

Condensed Consolidated Interim Financial Statements

For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited interim financial statements of the Company have been prepared by and are the responsibility of the Company's management.

The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

Condensed Consolidated Interim Statements of Financial Position

(Expressed in Canadian Dollars)

Assets	November 30, 2022	February 28, 2022
		(Note 4)
Current Assets:		
Cash and cash equivalents	\$ 1,912,503 \$	1,247,750
Marketable securities (Note 6)	3,097	7,910
Prepaid expenses (Note 7)	148,603	161,865
Sales tax and other receivables (Note 8)	47,497	21,423
	2,111,700	1,438,948
Non-Current Assets:		
Deposits	-	12,597
Equipment (Note 10)	518,045	180,529
Exploration and evaluation assets (Note 9)	-	1,344
Intangible assets (Note 12)	51,367	49,210
Prepaid expenses – long term (Note 7)	699,564	31,212
Right-of-use asset (Note 16)	-	9,962
Total Assets	\$ 3,380,676 \$	1,723,802
Liabilities and Equity		
Current Liabilities:		
Accounts payable and accrued liabilities (Note 15)	\$ 111,938 \$	166,119
Lease liability – current portion (Note 16)	-	12,167
Total Liabilities	111,938	178,286
Shareholders' Equity:		
Share capital (Note 17)	22,476,935	22,311,985
Reserves (Note 17)	7,728,336	7,792,453
Accumulated other comprehensive loss	(213,523)	(213,523
Deficit	(27,865,180)	(28,345,399
	2,126,568	1,545,516
Non-controlling interest ("NCI") (Note 5)	1,142,170	-
Total Shareholders' Equity	3,268,738	1,545,516
Total Liabilities and Shareholders' Equity	\$ 3,380,676 \$	1,723,802

Nature of Operations and Going Concern (Note 1) Contingency (Note 20)

Subsequent Event (Note 21)

Approved by the Board of Directors on January 26, 2023:

"Spencer Sung Bum Huh" , Director "Larry Okada" , Director

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Expressed in Canadian Dollars)

	For Three Months Ended November 30,			For Nine Nov	Month ember		
	2022		2021		2022		2021
Expenses			(Note 4)				(Note 4
Amortization (Notes 10 & 12)	\$ 29,119	\$	1,744	\$	66,745	\$	2,826
Amortization on ROU assets	-		14,943		9,962		44,828
Advertising and marketing	1,174		14,936		30,653		97,058
Consulting and management fees (Note 18)	87,643		129,463		371,542		362,330
Corporate listing and filing fees	5,805		2,341		31,768		85 <i>,</i> 505
Exploration and evaluation expenses	· -		9,000		· -		12,690
Investor relations	4,797		24,986		27,138		73,794
Office and general	6,544		20,778		31,227		38,405
Payroll expenses	128,387		-		338,190		-
Professional fees (Note 18)	60,775		47,465		161,103		123,202
Rent (non-lease portion)	18,092		28,192		83,449		64,253
Research and development (Note 11)	62,967		51,871		214,593		85,136
Sublease income	-		(10,602)		(5,925)		(38,637)
Stock-based compensation	_		(20,002,		-		683,248
Travel	10,904		8,858		32,208		27,795
Loss from operations	(416,207)		(343,975)		(1,392,653)		(1,662,433)
Other income (expense)							
Interest and miscellaneous income	379		_		379		58
Interest expense – lease (Note 16)	-		(2,786)		(1,857)		(9,679)
Interest expense - loan	_		(2,700)		(2,007)		(68,810)
Impairment of E&E assets (Note 9)	_		_		(1,344)		(00,010)
Gain (Loss) on foreign exchange	96,632		446		43,855		(2,256)
Unrealized gain (loss) on marketable securities	(1,980)		2,734		(4,813)		350
Write-off of debt	-		-		- (4,013)		65,845
Total other income (expense)	95,031		394		36,220		(14,492)
Net loss for the period	(321,176)		(343,581)		(1,356,433)		(1,676,925)
·		_		_			
Comprehensive loss for the period	\$ (321,176)	\$	(343,581)	\$	(1,356,433)	\$	(1,676,925)
Net loss Contributable to							
Controlling equity holders of the Company	(214,796)		(343,581)		(1,135,281)		(1,676,925)
Non-controlling interest (Note 5)	(106,380)		-		(222,152)		-
	(321,176)		(343,581)		(1,356,433)		(1,676,925)
Loss per share:		,		_			
Basic & Diluted	\$ (0.00)	\$	(0.00)	\$	(0.01)	\$	(0.02)
Weighted average number of common shares							
outstanding	97,878,979		90,734,713		97,837,694		84,752,798

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Cash Flows

(Expressed in Canadian Dollars)

		For Nine Months Ended		
	N	lovember 30, 2022	N	ovember 30, 2021
Operating Activities:				(Note 4)
Net loss for the period	\$	(1,356,433)	\$	(1,676,925)
Adjustment for items which do not involve cash:				
Amortization		66,745		2,826
Amortization on ROU assets		9,962		44,828
Stock-based compensation		-		683,248
Impairment of E&E assets		1,344		-
Unrealized loss on marketable securities		4,813		(350)
Write-off of accounts payable		-		(65,845)
Changes in non-cash working capital components:				(//
Accounts payable and accrued liabilities		(54,181)		(33,891
Deposits		12,597		(55,552
Short-term loan interest		,		68,809
Prepaid expenses		17,373		(152,397
Sales tax and other receivables		(26,074)		(7,117
		(1,323,854)		(1,136,814)
		(1,323,034)		(1,130,014)
Investing Activities:				
Prepaid expenses - commercial plant design fees		(672,463)		-
Equipment additions		(401,867)		(21,450)
Intangible assets additions		(4,551)		(10,873
		(1,078,881)		(32,323
Financing Activities:				2.057.000
Private placement		-		2,057,000
Repayment – share subscription		-		(25,000
Repayment – short-term loan principal and interest				(1,359,169
Exercise of warrants		53,333		1,660,000
Exercise of options		47,500		46,000
Principal portion of lease liability		(12,167)		(52,724
Proceeds from issuance of shares of Korean subsidiary		2,978,822		-
		3,067,488		2,326,107
Net changes in cash and cash equivalents		664,753		1,156,970
Cash and cash equivalents - beginning of the period				
		1,247,750	<u>,</u>	625,876
Cash and cash equivalents - end of the period	\$	1,912,503	\$	1,782,846

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Changes in Equity
For the Nine Months Ended November 30, 2022 and November 30, 2021
(Expressed in Canadian Dollars)

			SHARE		ACCUMULATED OTHER			NON-	
	SHARE (CAPITAL	SUBSCRIPTIONS		COMPREHENSIVE	ACCUMULATED	TOTAL FOR	CONTROLLING	
	SHARES	AMOUNT	RECEIVED	RESERVES	LOSS ("AOCL")	DEFICIT	OWNER	INTEREST	TOTAL EQUITY
						(Note 4)	(Note 4)		(Note 4)
Balance - February 28, 2021 Impact of change in accounting policy	70,233,980	18,935,514	25,000	6,733,711	(213,523)	(26,315,235)	(834,533)	-	(834,533)
(Note 4)	-	-	-	-	-	34,515	34,515	-	34,515
Restated Balance - February 28, 2021	70,233,980	18,935,514	25,000	6,733,711	(213,523)	(26,280,720)	(800,018)	=	(800,018)
Repayment – share subscription	-	-	(25,000)	-	-	-	(25,000)	-	(25,000)
Share issued – private placement	17,141,667	57,413	-	1,999,587	-	-	2,057,000	-	2,057,000
Stock-based compensation	-	-	-	683,248	-	-	683,248	-	683,248
Exercise of stock options	650,000	95,166	-	(49,166)	-	-	46,000	-	46,000
Exercise of warrants	9,500,000	2,679,406	-	(1,019,406)	-	-	1,660,000	-	1,660,000
Net loss for the period	-	-	-	-	-	(1,676,925)	(1,676,925)	-	(1,676,925)
Balance - November 30, 2021	97,525,647	21,767,499	-	8,347,974	(213,523)	(27,957,646)	1,944,304	-	1,944,304
Balance – February 28, 2022	97,525,647	22,311,985	-	7,792,453	(213,523)	(28,394,609)	1,496,306	-	1,496,306
Impact of change in accounting policy (Note 4)	-	-	-	-	-	49,210	49,210	-	49,210
Restated Balance - February 28, 2022	97,525,647	22,311,985	-	7,792,453	(213,523)	(28,345,399)	1,545,516	-	1,545,516
Exercise of warrants (Note 17)	333,332	70,566	-	(17,233)	-	-	53,333	-	53,333
Stock options exercise (Note 17)	745,000	94,384	-	(46,884)	-	-	47,500	-	47,500
Issuance of shares in Korea Co (Note 5)	-	-	-	-	-	1,615,500	1,615,500	1,363,322	2,978,822
Net loss for the period		-	-	-		(1,135,281)	(1,135,281)	(221,152)	(1,356,433)
Balance - November 30, 2022	98,603,979	22,476,935	-	7,728,336	(213,523)	(27,865,180)	2,126,568	1,142,170	3,268,738

The accompanying notes are an integral part of these condensed consolidated interim financial statements

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

1. Nature of Operations and Going Concern

NEO Battery Materials Ltd. (the "Company" or "NEO Battery") is a publicly listed company incorporated under the Business Corporations Act of British Columbia on February 10, 2006 as 0748496 B.C. Ltd. On March 1, 2006, the Company changed its name to BCGold Corp, and on March 16, 2017 to Pan Andean Minerals Ltd, and again on March 2, 2021, to NEO Battery Materials Ltd. The Company is listed on the TSX Venture Exchange ("TSX.V" or the "Exchange") under the symbol "NBM". The head office, principal address and records office of the Company are located at Suite 700 – 838 West Hastings Street, Vancouver, British Columbia, Canada, V6C 0A6. The Company's registered address is Suite 1500 - 1055 West Georgia Street, Vancouver, British Columbia, Canada, V6E 4N7.

On April 13, 2022, the Company commenced a "Change of Business" (the "COB") application with the Exchange. In the past, the Company was a Vancouver-based junior resource company with exploration in North America. The Company deems that a classification to a Tier 2 Technology issuer on the Exchange instead of a junior Mineral Exploration and Mining issuer will better reflect the Company's long-term goal and serve its shareholders' best interests. This transition is in process and subject to Exchange acceptance as of the date of these financial statements. On November 21, 2022, the Company received the conditional approval from Exchange for proposed COB into an Industrial, Technology, or Life Sciences Tier 2 Issuer.

The Company's ability to continue as a going concern on the is highly dependent upon its ability to obtain the financing necessary to continue operation. The key risk to the Company's sustainability is securing the funding for its commercial plant's construction in the near term. The Company's operation is highly influenced by the capital market environment, supply chain, inflation, geographic stability, and global business environment in general.

These unaudited condensed consolidated interim financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations. The Company continues to incur operating losses, has limited financial resources, no source of operating cash flow, and no assurances that sufficient funding, including adequate financing, will be available to continue operations. These material uncertainties may cast a significant doubt on the validity of this assumption. As at November 30, 2022, the Company had an accumulated deficit of \$27,865,180 (February 28, 2022 - \$28,345,399), a net loss for the period ended November 30, 2022 of \$1,356,433 (November 30, 2021 - \$1,676,925) and working capital of \$1,999,762 (February 28, 2022 - \$1,260,662).

If the going concern assumption is not appropriate for these consolidated financial statements, adjustments could be necessary in the carrying values of assets, liabilities, reported income and expenses and the statement of financial position classifications used. Such adjustments could be material.

2. Basis of Preparation

Statement of Compliance

These unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 – Interim Financial Reporting as issued by the International Accounting Standards Board ("IASB"). Accordingly, certain disclosures included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the IASB have been condensed or omitted and these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended February 28, 2022.

The amended condensed consolidated interim financial statements were authorized for issue by the Board of Directors on January 26, 2023.

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

2. Basis of Preparation - continued

Basis of Presentation and Consolidation

These condensed consolidated interim financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit or loss, which are stated at their fair value. In addition, these consolidated financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

Control is based on whether an investor has power over the investee and the ability to use its power over the investee to affect the amount of the returns.

Where the Company's interest is less than 100%, the interest attributable to outside shareholders is reflected in non-controlling interest. Non-controlling interests in the net assets of consolidated subsidiaries are identified separately from the Company's equity therein. Non-controlling interests consist of the amount of those interests at the date that the Company's interest dropped below 100% and the non-controlling interests' share of changes in equity since that date.

These condensed consolidated interim financial statements incorporate the financial statements of the Company and the entities controlled (directly or indirectly) by the Company (its subsidiaries) including Neo Battery Materials Korea Co, Circum-Pacific Holdings Ltd., Canada, Minera Chanape SAC, Peru and Cima De Oro SAC, Peru. All significant intercompany transactions and balances have been eliminated.

The current non-controlling interest represents a 40% interest in Neo Battery Material Korea Co (Note 5).

Critical Accounting Estimates

The preparation of these consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported expenses during the period. Actual results could differ from these estimates.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

- i) The incremental rate of borrowing used in the measurement of the lease liability was based on estimated interest rate the Company would borrow at from arm's-length third parties as at the dates of adopting IFRS 16 and entering into its current long-term office lease.
- The inputs used in accounting for stock-based compensation expense included in profit or loss calculated using the Black-Scholes option pricing model.
- iii) The valuations of shares issued in non-cash transactions using the quoted share price as the fair value-based measurement on the date the shares are issued for the transaction.
- iv) The recognition of deferred tax assets based on the change in unrecognized deductible temporary tax differences.
- v) The estimated useful lives of the intangible assets.

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

2. Basis of Preparation - continued

Recent accounting pronouncements

A number of new standards, and amendments to standards and interpretations, were not yet effective for the period ended November 30, 2022, and have not been early adopted in preparing these consolidated financial statements. These new standards, and amendments to standards and interpretations were either not applicable or are not expected to have material impact on the company's condensed consolidated interim financial statements.

3. Significant Accounting Policies

Intangible Assets

Intangible assets with finite lives are measured at cost less accumulated amortization and impairment losses. These intangible assets are amortized on a straight-line basis over their estimated useful lives. Useful lives, residual values, and amortization methods for intangible assets with finite useful lives are reviewed at least annually.

The patents classified as intangible assets are being amortized over their useful lives, being 16 or 17 years.

The trademark classified as intangible assets are not amortized since they retain their value forever.

Indefinite life intangible assets are measured at cost less any impairment charges. These intangible assets are tested for impairment on an annual basis or more frequently if there are indicators that the intangible assets may be impaired.

4. Change in Accounting Policy

The Company is applying a change to its accounting policy relating to the treatment of license fees under IAS 38 *Intangible Assets*. The Company had previously expensed as incurred. The Company has adopted the policy, as outlined in Note 3 – Significant Accounting Policies above, to capitalize the license and patents registration fees. The Company had previously expensed these fees on the statement of loss and comprehensive loss.

With the change, the Company aims to improve its financial communication by providing more reliable, clear and relevant information regarding the Company's intangible assets to its peers in the industry.

The following summarizes the impact of the change in accounting policy on the financial statement line items impacted in these financial statements:

Consolidated Statement of Financial Position as at February 28, 2022:

	As reported	Adjustment	Restated Balance
	(\$)	(\$)	(\$)
Intangible Assets	-	49,210	49,210
Total Assets	1,674,592	49,210	1,723,802
Deficit	(28,394,609)	49,210	(28,345,399)
Shareholders' Equity	1,496,306	49,210	1,545,516
Total Liabilities and Shareholders' Equity	1,674,592	49,210	1,723,802

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

4. Changing Accounting Policies – continued

Consolidated Statement of Loss and Comprehensive Loss for the nine months ended November 30, 2021:

	As reported	Adjustment	Restated Balance
	(\$)	(\$)	(\$)
Amortization	1,073	1,753	2,826
License fees	10,000	(10,000)	-
Professional fees	124,075	(873)	123,202

Consolidated Statement of Change in Equity for the nine months ended November 30, 2021:

	As reported (\$)	Adjustment (\$)	Restated Balance (\$)
Deficit, as at February 28, 2021	(26,315,235)	34,515	(26,280,720)
Total Shareholders' Equity, as at			
February 28, 2021	(834,533)	34,515	(800,018)
Net Loss for the nine months ended			
November 30, 2021	(1,686,045)	9,120	(1,676,925)
Deficit, as at November 30, 2021	(28,001,281)	43,635	(27,957,646)
Total Shareholders' Equity, as			
at November 30, 2021	1,900,669	43,635	1,944,304

Consolidated Statement of Cash Flow for the nine months ended November 30, 2021:

	As reported (\$)	Adjustment (\$)	Restated Balance (\$)
Net loss for the nine months ended			
November 30, 2021	(1,686,045)	9,120	(1,676,925)
Amortization	1,073	1,753	2,826
Cash used in operating activities	(1,147,687)	10,873	(1,136,814)
Cash used in investing activities	-	(10,873)	(10,873)

5. Non-controlling Interest

On July 1, 2022, Neo Battery Materials Korea Co ("Korea Co"), a wholly-owned subsidiary of the Company, entered into an Investment Agreement with Automobile & PCB Inc. ("A&P"). Under the terms of Investment Agreement, Korea Co issued 517,657 common shares to A&P at a price of \$5,796 South Korea Won ("KRW") per common share for aggregate gross proceeds of \$2,999,820,383 KRW (equivalent to CAD \$2,978,822). Upon closing of the Investment Agreement, A&P acquired 40% of the issued and outstanding common shares of Korea Co, leaving the Company with a 60% ownership interest in Korea Co on an issued and outstanding basis.

The Company controls and therefore includes the accounts of NEO Korea Co in these consolidated financial statements. A non-controlling interest ("NCI") of \$1,363,322 was recognized as being equal to 40% of the net assets of NEO Korea Co immediately after completion of the Investment Agreement. As funds are expended by NEO Korea Co, it is anticipated that losses will arise in that entity, which will reduce the collective NCI amount, recorded within equity, by its pro-rata share of such losses. The Company's share of such losses would be included within its expenses on a consolidated basis. Likewise on a consolidated basis the losses of NEO Korea Co attributable to the NCI would reduce the Company's reported loss.

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

5. Non-controlling Interest - continued

As at November 30, 2022, the details of the NCI are as follows:

Non-controlling interest in net asset given up	\$ 1,363,322
Net loss of NEO Korea Co attributable to the non-controlling interest	(221,152)
Non-controlling interest as at November 30, 2022	\$ 1,142,170

6. Marketable Securities

As at November 30, 2022, marketable securities include 100,000 common shares of a publicly traded company, Pembridge Resources PLC, valued at \$3,097 (February 28, 2022 - \$7,910).

	November 30, 2022	February 28, 2022
	\$	\$
Marketable securities – fair value	3,097	7,910
Marketable securities – cost	22,200	22,200

7. Prepaid Expenses

	November 30, 2022	February 28, 2022
	\$	\$
Prepaid Expenses - current		
Insurance	4,697	4,579
Rent (a)	14,746	43,736
Travel	8,932	10,550
Vendors	120,228	103,000
Short-term prepaid	148,603	161,865
Prepaid Expenses – long term		_
Insurance (b)	27,110	31,212
Vendors (c)	672,463	-
Long-term prepaid	699,564	31,212
Total	848,167	193,077

- (a) Includes payments made to rent a site to build the Company's commercial plant in South Korea for the period from September 1, 2022 to December 31, 2022.
- (b) Includes an insurance payment made to guarantee the deposit held for building the Company's commercial plant in South Korea for the period from March 1, 2023 to February 28, 2032.
- (c) Includes payments made to building and process design fees for the Company's commercial plant in South Korea. Such costs will be reclassified to buildings upon the completion of the facility.

8. Sales Tax Receivables

	November 30, 2022	February 28, 2022
	\$	\$
Sales tax (GST & VAT)	47,497	21,423

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

9. Exploration and Evaluation Assets and Expenditures

Details of the Company's exploration and evaluation acquisition costs are as follows:

	November 30, 2022	February 28, 2022
	\$	\$
Beginning of the period	1,344	1,344
Impairment	(1,344)	-
Carrying value – end of the period	-	1,344

In connection with the COB, the Company impaired its remaining exploration and evaluation assets during the nine months ended November 30, 2022.

10. Equipment

The Company purchased equipment for its research and development center, located at Yonsei University ("Yonsei"), South Korea. Such equipment has alternative uses in other business if the Company, in the future, ceases the research and development activities.

The net book value of the Company's equipment is as follows:

	Equipment	Total
Cost:		
February 28, 2021	\$ -	\$ -
Additions	192,761	192,761
February 28, 2022	192,761	192,761
Additions	401,867	401,867
November 30, 2022	\$ 594,628	\$ 594,628
Accumulated Amortization:		
February 28, 2021	\$ -	\$ -
Additions	(12,232)	(12,232)
February 28, 2022	(12,232)	(12,232)
Additions	(64,351)	(64,351)
November 30, 2022	\$ (76,583)	\$ (76,583)
Net Book Value:		
February 28, 2022	180,529	180,529
November 30, 2022	\$ 518,045	\$ 518,045

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

11. Research and Development

On August 23, 2022, NEO Korea Co entered an Industrial Advice Agreement ("the Agreement") with Yonsei to replace the original Collaborative Development Agreement signed between the Company and Yonsei on May 10, 2021. The term of the Agreement runs from August 1, 2022 to May 31, 2023, over which time NEO Korea Co will be responsible for research and development costs of approximately \$125,970 (South Korea Won ("KRW") 130,000,000).

During the nine months ended November 30, 2022, the Company incurred research and development costs of \$214,593, of which \$103,763 (November 30, 2021 - \$77,208) was in connection with the Agreement.

12. Intangible Assets

Patents

On February 8, 2021, the Company entered into an Exclusive License Agreement with Yonsei (the "1st Agreement") to obtain exclusive rights to use the three patents owned by Yonsei. Under the terms of the 1st Agreement, the Company paid an initial license fee of \$35,030 during the year ended February 28, 2021. The remaining license fee of \$267,887 will be due upon the first sale of the product produced based on the use of the patents.

On July 22, 2021, the Company entered into a second Exclusive License Agreement with Yonsei (the "2nd Agreement") to obtain exclusive rights to use a separate patent owned by Yonsei. Under the term of the 2nd Agreement, the Company paid an initial license fee of \$10,000 during the year ended February 28, 2022. The remaining license fee of \$40,000 will be due upon the first sale of the product produced based on the use of the patent.

The Company also incurred \$7,119 of registration fees, documentation fees and other professional fees associated with patent registration during the year ended February 28, 2022 (2021 - \$nil).

Trademark

On December 24, 2021, the Company filed the Trademark "NBMSiDE" with Korean Intellectual Property Office and incurred \$1,472 of application fee. As at November 30, 2022, the application fee is classified as intangible asset without being amortized (Note 3).

As at November 30, 2022, intangible assets include one trademark, three registered patents and two patents pending registration. For the purpose of calculating amortization, all of the patents have an expiry date of February 8, 2038.

The net book value of the Company's intangible assets is as follows:

	Patents	Trademark	Total
Cost:			
February 28, 2021	\$ 35,030	\$ -	\$ 35,030
Additions	17,119	-	17,119
February 28, 2022	52,149	-	52,149
Additions	3,079	1,472	4,551
November 30, 2022	\$ 55,228	\$ 1,472	\$ 56,700

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

\$

(Expressed in Canadian Dollars)

12. Intangible Assets - continued

Accumulated Amortization	n:			
February 28, 2021	\$	(515)	\$ -	\$ (515)
Additions		(2,424)	-	(2,424)
February 28, 2022		(2,939)	-	(2,939)
Additions		(2,394)	-	(2,394)
November 30, 2022	\$	(5,333)	\$ -	\$ (5,333)
Net Book Value:				
February 28, 2022	\$	49,210	\$ -	\$ 49,210

49,895

1,472

\$

51,367

(see Note 4)

13. Financial Risk and Capital Management

November 30, 2022

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is summarized as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash held in bank accounts. The majority of cash is deposited in bank accounts at a major bank in Canada and a major bank in South Korea. As most of the Company's cash is held by two banks there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. The Company's exposure to credit risk is minimal.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash.

Historically, the Company's sole source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to necessary levels of equity funding. The Company manages liquidity by maintaining a certain level of cash balances to meet liabilities as they become due. As at November 30, 2022, the Company has a cash balance of \$1,912,503 and current liabilities of \$111,938.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and commodity and equity prices. The Company's financial instruments include investments which are publicly traded and therefore subject to the risks related to the fluctuation in the equity markets. The Company closely monitors market values to determine the most appropriate course of action.

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

13. Financial Risk and Capital Management - continued

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company's cash, accounts receivable, and accounts payable and accrued liabilities are held in CAD and in KRW; therefore, KRW accounts are subject to fluctuation against the CAD.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to significant interest rate risks.

Capital management

The Company's policy is, if permitted by market conditions, to maintain a strong capital base so as to support investor and creditor confidence and support future development of the business. The capital structure of the Company consists of equity, comprising share capital and reserves net of accumulated deficit. The Company is not subject to any externally imposed capital requirements.

14. Financial Instruments

The three levels of the friar value hierarchy are as follows:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities in active markets;
- Level 2 Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active market; quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data; and
- Level 3 Unobservable inputs which are supported by little or no market activity.

As required by IFRS 13, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Cash and marketable securities are measured at fair value using Level 1 inputs.

As at November 30, 2022, the Company's marketable securities are valued based on the closing trading price of the shares on public stock exchange at the year-end date.

15. Accounts Payable and Accrued Liabilities

	November 30, 2022	February 28, 2022
	\$	\$
Trade payables	108,769	149,639
Accrued liabilities	3,169	16,480
Total	111,938	166,119

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

16. Right-Of-Use Asset & Lease Liability

The Company had an office lease for the period from May 1, 2019 to April 30, 2022. Minimum annual commitments for basic rent, excluding additional operating costs, were as follows:

Year	Amount		
2020	\$ 64,362		
2021		80,032	
2022	83,390		
2023	13,992		
	\$	241,776	

(a) Right-of-use asset

As at November 30, 2022 and February 28, 2022, the carrying value of the Company's right-of-use asset for its office lease was as follows:

	November 30, 2022	February 28, 2022
	\$	\$
Opening balance	9,962	69,733
Amortization	(9,962)	(59,771)
Ending balance	<u> </u>	9,962

(b) Lease liability

Minimum lease payment in respect of the office lease liability and the effect of discounting as at November 30, 2022 and February 28, 2022 were as follows:

	November 30, 2022 \$	February 28, 2022 \$
Undiscounted minimum lease payment:	· ·	·
Less than one year	-	13,992
More than one year		<u>-</u>
Total undiscounted minimum lease payment	-	13,992
Effect of discounting		(1,825)
Present value of minimum lease payment	-	12,167
Less: current portion		(12,167)
Long-term portion	-	-

(c) Lease liability continuity

The net changes in the Company's lease liability during the periods ended November 30, 2022 and February 28, 2022 were as follows:

November 30, 2022	February 28, 2022
<u> </u>	\$
12,167	83,093
(12,167)	(70,926)
<u> </u>	12,167
	\$ 12,167 (12,167)

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

16. Right-Of-Use Asset & Lease Liability - continued

(d) Lease liability interest and sublease income

During the nine months ended November 30, 2022, the Company recorded \$1,857 (2022 - \$6,893) of interest expense on the lease liability and received \$5,925 (2022 - \$28,035) of sublease income.

17. Share Capital

The Company's authorized share capital consists of an unlimited number of common voting shares without par value.

Private Placements

Nine Months Ended November 30, 2022

The Company did not complete any private placements during the nine months ended November 30, 2022.

Year Ended February 28, 2022

On May 4, 2021, the Company completed a non-brokered private placement of 17,141,667 units at a price of \$0.12 per unit for gross proceeds of \$2,057,000. Each unit consisted of one common share and one common share warrant, with each warrant entitling the holder to purchase one common share at a price of \$0.16 per common share for 36 months from the closing date of the private placement. Under the fair value method, \$886,000 of the proceeds were allocated to the warrants. The fair value of the warrants was calculated using the Black-Scholes Option Pricing Model with the following assumptions: 0.49% risk-free interest rate, 3 years of expected life, 218% volatility and 0% dividend rate.

Share issuance - Exercise of Warrants

Nine Months Ended November 30, 2022

During the nine months ended November 30, 2022, 333,332 warrants were exercised at a price of \$0.16 per warrant for total proceeds of \$53,333. Upon the exercise of the warrants, \$17,233 of the fair value of the warrants recorded was transferred from reserves to share capital.

Year Ended February 28, 2022

During the year ended February 28, 2022, 1,000,000 and 8,500,000 warrants were exercised at a price of \$0.30 and \$0.16 per warrant, respectively, for total proceeds of \$1,660,000. Upon the exercise of the warrants, \$465,340 of the fair value of the warrants recorded was transferred from reserves to share capital.

Share issuance - Exercise of Stock Options

Nine Months Ended November 30, 2022

During the nine months ended November 30, 2022, 725,000 stock options and 20,000 stock options were exercised at a price of \$0.06 and \$0.20 per share, respectively, for total proceeds of \$47,500. Upon the exercise of the options, \$46,884 of the fair value of the options recorded was transferred from reserves to share capital (Note 21).

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

17. Share Capital – continued

Year Ended February 28, 2022

During the year ended February 28, 2022, 600,000 and 50,000 stock options were exercised at a price of \$0.06 and \$0.20 per share, respectively, for total proceeds of \$46,000. Upon the exercise of the options, \$45,166 of the fair value of the options recorded was transferred from reserves to share capital.

Share Purchase Warrants

Share purchase warrant transactions are summarized as follows:

	Number of Warrants	Weighted Average Exercise Price
		\$
Balance, February 28, 2021	4,500,000	0.30
Issued	17,141,667	0.16
Exercised	(9,500,000)	0.17
Expired	(3,500,000)	0.30
Balance, February 28, 2022	8,641,667	0.16
Exercised	(333,332)	0.16
Balance, November 30, 2022	8,308,335	0.16

As at November 30, 2022, outstanding warrants are as follows:

			Weighted Average
			Life Remaining
Expiry Date	Exercise Price (\$)	Number of Warrants	(Years)
May 4, 2024	0.16	8,308,335	1.43

Stock Options

The Company has established a stock option plan (the "Plan") for directors, employees, and consultants of the Company. From time to time, shares may be reserved by the Board, in its discretion, for options under the Plan, provided that at the time of the grant, the total number of shares so reserved for issuance by the Board shall not exceed the greater of 10% of the issued and outstanding listed shares (on a non-diluted basis) as at the date of grant. No options shall be granted, without regulatory approval, entitling any single individual to purchase in excess of 5% of the then outstanding shares in the Company in any 12-month period and no more than 2% of the optioned shares may be issued to any one individual in any 12-month period. If the option rights granted under the plan shall expire or terminate for any reason without having been exercised, such optioned shares may be made available for other options to be granted under the plan. The shares so reserved by the Board under the Plan shall be authorized but unissued shares.

The options are non-transferable and will expire, if not exercised, immediately upon dismissal by the Company with cause or 90 days following the date the optionee otherwise ceases to be a director, officer, manager, consultant or employee of the Company for reasons other than death. In the case of death, the expiry becomes one year after the death of an optionee. Pursuant to the policies of the TSX.V, options granted pursuant to the Plan in excess of 10% of the issued and outstanding common shares at the time of the grant must be subject to vesting.

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

17. Share Capital – continued

Stock Options – continued

The Board has previously established a rolling Stock Option Plan which reserves for issuance up to 10% of the Company's outstanding common shares. The policies of the TSX Venture exchange require such stock option plans to be approved annually by the Company's shareholders by way of an ordinary resolution. Shareholder approval shall be sought at the next AGM for the Stock Option Plan, as such, any options issued prior to such approval shall not be exercisable until such approval is granted by shareholders.

Stock option transactions are summarized as follows:

	Number of Options	Weighted Average Exercise Price
	•	\$
Balance, February 28, 2021	6,505,000	0.12
Granted	1,350,000	0.65
Corrected (canceled by error)	150,000	0.06
Exercised	(650,000)	0.07
Canceled	(90,000)	0.20
Balance, February 28, 2022	7,265,000	0.22
Exercised	(745,000)	0.20
Canceled	(40,000)	0.33
Balance, November 30, 2022	6,480,000	0.24

As at November 30, 2022, outstanding stock options are as follows:

Expiry Date	Weighted Average Exercise Price	Number of Options Outstanding	Number of Options Exercisable	Weighted Average Remaining Life (Years)
March 21, 2023	\$0.06	1,000,000	1,000,000	0.30
February 28, 2024	\$0.06	1,400,000	1,400,000	1.25
February 10, 2026	\$0.20	2,840,000	2,840,000	3.20
May 13, 2026	\$0.20	320,000	320,000	3.45
May 25, 2026	\$0.20	30,000	30,000	3.48
June 1, 2026	\$0.20	100,000	100,000	3.50
June 9, 2026	\$0.33	40,000	40,000	3.53
July 30, 2026	\$1.00	750,000	750,000	3.67
	\$0.24	6,480,000	6,480,000	2.41

18. Related Party Transactions

Related parties include the Company's key management personnel with authority and responsibility for planning, directing and controlling activities of the Company. The Company has determined that its key management personnel is comprised of the Company's Board of Directors and officers, and the entities controlled by the key management personnel.

Notes to the Condensed Consolidated Interim Financial Statements For the Nine Months Ended November 30, 2022 and November 30, 2021

(Expressed in Canadian Dollars)

18. Related Party Transactions - continued

As at November 30, 2022 and February 28, 2022, there were no balances due to related parties.

During the nine months ended November 30, 2022 and 2021, the Company paid the following amount to the officers and directors of the Company and an entity controlled by the CEO:

	November 30, 2022		November 30, 2021	
Management fees	\$	233,027	\$	141,800
Professional fees		71,310		41,452
Project related – Exploration and evaluation		-		12,690
	\$	304,337	\$	195,942

19. Segmented Information

The Company currently operates in two geographic segments: Canada and South Korea. No industry segregation is given because the Company's mineral activities are not material.

	Canada (\$)	Korea (\$)	Total (\$)
Total assets	166,727	3,213,949	3,380,676
Total liabilities	98,533	13,405	111,938

20. Contingency

A former director of the Company ("Plaintiff") filed a Notice of Civil Claim (the "Claim") against the Company on December 17, 2021 in the Supreme Court of British Columbia seeking a court order compelling the Company to accept his exercise of the Company's stock options granted to him on March 21, 2018 and to issue to him 350,000 common shares of the Company upon the receipt of payment of \$21,000 (the "Order"). On January 25, 2022, the Company filed a response to the Claim to appeal against the Order.

As at November 30, 2022, the final conclusion of the Claim was indeterminable and no amount of contingency was recorded (Note 21).

21. Subsequent Events

In December 2022, 1,133,333 stock options were exercised at price of \$0.06 for a total of proceeds of \$68,000.

On January 3, 2023, the Company received a notice of application hearing from Plaintiff. The hearing is scheduled on February 22, 2023.

On January 17, 2023, the Company received approval of construction permit for Silicon Anode Commercial Plant in Oseong Foreign Investment Zone, Pyeongtaek City.